Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Epirubicin and mitoxantrone (novantrone) are both anthracycline-type chemotherapy drugs that have been studied in combination with other agents like fluorouracil and cyclophosphamide for treating metastatic breast cancer. Both drugs work by interfering with DNA synthesis and function, with epirubicin being a 4'-epi-isomer of doxorubicin. In clinical trials, epirubicin-containing regimens (FEC) showed better response rates than mitoxantrone-containing regimens (FNC), particularly in previously untreated patients and postmenopausal women. The main difference between these drugs is their toxicity profile - epirubicin causes more complete alopecia while mitoxantrone causes more significant hematological toxicity (leukopenia and thrombocytopenia).
- Other names
- FEC + FNC
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + mitoxantrone.